Kidney International, Vol. 50 (1996), pp. 1753—1 766

NEPHROLOGY FORUM

Goodpasture's syndrome Principal discussant: W. KLINE BOLTON

University of Virginia Health Sciences Center, Charlottesville, Virginia, USA

serum protein and albumin were normal. Blood gases obtained while the patient was breathing room air were: pH, 7.37; PaCO2, 33 mm Hg; and Editors Pa02, 80 mm Hg. A chest radiograph revealed a new right upper lobe JORDAN J. COHEN infiltrate (Fig. 1). Urinalysis showed 3+ protein, large blood, dysmorphic JOHN T. HARRINGTON red blood cells, granular casts, and red cell casts. The patient was admitted to the hospital for further workup. He NIc0LAOs E. MADIAS underwent bronchoscopy with broneho-alveolar lavage (BAL) as well as ventilation/perfusion scan. Culture and cytologic examinations of the BAL Managing Editor fluid were negative, and the sean was interpreted as a low probability for CHERYL J. ZUSMAN pulmonary embolus. The assay for anti-neutrophil eytoplasmic (ANCA) was positive at 1:1280 with a perinuclear pattern of fluorescence. to the glomerular (GBM) were negative by indirect fluorescence assay. Renal contained 13 glomeruli, 5 of Tufts University School of Medicine which were globally sclerotic and obsolescent. The remaining 8 had varying degrees of hypercellularity and segmental sclerosis; two demon- strated epithelial crescents (Fig. 2). The interstitium showed a moderate amount of tubular atrophy and fibrosis with a mild mononuclear cell infiltrate. No was seen. Immunofluorescent examination re- vealed IgG in a moderately intense linear pattern along the GBM and a Case presentation similar pattern of staining for kappa and lambda light chains (Fig. 3). C3 A 59-year-old white man with a history of recurrent pleural effusions, was found only in the mesangium without GBM staining. Fibrin was coal worker's pneumoconiosis, and a positive PPD presented with hemop- present in glomerular crescents (Fig. 3). Electron microscopy revealed no tysis beginning on the morning of admission. The patient had coughed up immune deposits. Anti-GBM assay by ELISA was positive against the small amounts of dark blood totaling approximately 4 ounces; although recombinant rs3(IV) NC1 domain. this was his first episode of , he had experienced epistaxis The patient was treated with , 70 mg/day, and 200 mg daily of eyclophosphamide, which was tapered over six months. Over a period of approximately once weekly in the previous year. The patient was married, had smoked one pack of cigarettes/day for 30 years, but had quit four years one month, the patient's serum creatinine concentration returned to 1.4 ago. He occasionally drank alcoholic beverages, and he was a retired coal mg/dl with a BUN of 36 mg/dl. At that time, the urinary sediment showed miner who had worked directly in the mines. He denied , chills, night only an occasional red cell with no red cell casts. sweats, weight loss, decreased appetite, nausea, vomiting, , or cough. The patient complained of a transient nonspecific rash in Discussion the previous weeks that had resolved. The medical history was notable for a recurrent left-sided pleural DR. W. KUNE BOLTON (Chief Division of , and effusion 5 years previously with a negative workup for -vascular disease, malignancy, and . He had had nephrotic-range protein- Professor of Medicine, University of Virginia Health Sciences Center, uria four years prior to admission; renal biopsy then demonstrated focal Charlottesville, Virginia): The present case was selected to illus- segmental glomeruloselerosis. Treatment with an angiotensin-converting- trate some of the typical features seen with Goodpasture's enzyme inhibitor reduced the to below 400 mg/24 hours. The syndrome (GPS), as well as some of the atypical features that are family history was negative. of major clinical importance to the practicing nephrologist. This Physical examination revealed a well-appearing white man in nopatient also illustrates some new ideas in diagnosis, prognosis, and apparent distress. His temperature was 37°C; respirations, 20/mm; pulse, 80 beats/mm; and blood pressure, 120/60 mm Hg. The head, eyes, ears, therapy. The term "GPS" is an eponym derived from a report in nose, and throat were normal, as was the neck. The lungs were clear to 1919 by Ernest Goodpasture, who described the clinical syndrome auscultation. Cardiac examination was unremarkable. His abdomen was of pulmonary hemorrhage associated with influenza infection and soft, nontender, and his extremities showed no evidence of clubbing, the histologic finding of acute creseentic (GN) cyanosis, or . Neurologic examination was normal. Laboratory evaluation revealed a white blood cell count of 9700/mm3; [1, 21.Wedo not, as a matter of fact, know that the patients hematocrit, 41%; and , 192,000/mm3. Blood urea nitrogen (BUN) described by Goodpasture had anti-GBM disease. Over the years, was 40 mgJdl and serum creatinine concentration 2.3 mg/dl; two months the terminology has been used in different ways by different ago, the BUN was 25 mg/dl and the serum ereatinine, 1.4 mg/dl. Total individuals, some including all causes of pulmonary hemorrhage with renal dysfunction as GPS [3]. Others limited the term GPS to patients with pulmonary hemorrhage associated with anti-GBM The Nephrology Forum is funded in part by grants from Amgen,antibodies, as opposed to GN with anti-GBM antibodies but Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorporated; without pulmonary hemorrhage [4]. Yet others espouse the and R & D Laboratories. concept of anti-type-TV rather than GPS [5]. © 1996 by the International Society of Nephrology Although most of the antibody activity is directed to the

1753 1754 NephrologyFonim: Goodpasture r syndrome

Fig. 1. Chestroentgenogramshowing right upper lobe infiltrate which appeared coincident with hemoptysis.

a3(IV)NCI domain of type-IV collagen, antibody to other chainsbe able to develop more rational and specific forms of therapy for and other constituents of the GBM can occur [6—8]. Indeed,GPS. studies both in humans and animal models demonstrate that many different anti-GBM antibody specificities are found clinically, and Epidemiology and clinical manifestations that although all these antibodies fix to the GBM, the resultant Goodpasture's syndrome is uncommon, having an incidence of clinical phenotypes can be quite different. Since the target anti-approximately 0.1 cases per million population. In our experience, gen(s) (GBM) appear to be the same regardless of the clinicalit accounts for approximately 1% to 2% of renal biopsy specimens presentation, and anti-GBM-associated clinical findings can range[9]. The distribution by gender is approximately equal, with a very from normal renal function with asymptomatic GBM depositsslight preponderance of males to females. The age at presentation without pulmonary symptoms, to pulmonary hemorrhage with orcan range from the first to the ninth decade, so the commonly held without GN, to GN with or without pulmonary involvement, itconcept that this is a disease of young males is of little clinical seems impractical to subdivide thc clinical presentation based onlypracticality. There is, however, a bimodal distribution, with a on the presence or absence of pulmonary hemorrhage. I thereforegreater number of individuals presenting around age 30 and a consider any patient with anti-GBM antibodies deposited in tissuesecond peak at around age 60 [10]. This latter group has a slighter as having GP disease, and patients with GP disease and GN orgreater tendency for female distribution and GN rather than hemoptysis or both as having GP syndrome. Thus the antibodiespulmonary hemorrhage, but these tendencies are of little clinical and target are the common link among the variousimportance. The disease is more common in whites than in clinical presentations, and it is the environmental and secondaryAfrican-Americans and may be more common in certain other effector systems that determine the clinical presentation. In thisracial groups, such as the Maoris in New Zealand [111. Goodpas- context, patients who have had renal transplants and recurrentture's syndrome can present year round, but its incidence appears anti-GBMantibody on the basement membrane without pulmo-to increase in the spring and early summer; some localized nary hemorrhage and without GN are still classified as part of theoutbreaks have been associated with infection. In our experience, spectrum of GP disease, as are symptomatic and asymptomaticapproximately one-half to three-quarters of patients have some allografted patients with Alport's syndrome who have de-novotype of pulmonary presentation, such as cough, or upper respira- anti-GBM antibody deposits. It seems likely that, as we gain atory tract infection, plus fever, rash, myalgia, malaise, , better understanding of the pathogenesis of this disease, we willweight loss, or other vague . be able to define why the clinical spectrum is so variable and will In patients with renal involvement, an active urinary sediment Nephrolo Fomm: Goodpasture 's syndrome 1755

Fig. 2. Light microscopic photograph showing Jical segmental glomerular sclerosis. A, first biopsy; B, a glomerulus with a crescent (arrow), second biopsy.

with dysmorphic red cells and red cell casts is extremely common.months [9, 12—14]. We define rapidly progressive GM (RPGN), If urinary findings are not present, one should consider otherfrequently seen in GPS, as a halving of GFR or doubling of serum diseases. Proteinuria usually is present, hut not in the ncphroticcrcatinine within three months or less [91. range, although an occasional patient will have heavy proteinuria. Inpatients who also have pulmonary involvement, the presen- Significant is usually not a feature of the disease, buttation is nonspecific; GPS is but one of many causes of pulmonary mild increases in blood pressure consistent with age do occur.hemorrhage (Table 1). These causes include vasculitis (including Ultrasonography reveals normal-sized kidneys with normal echo-most importantly, microscopic , Wegener's texture and without anatomic abnormality. Renal function cangranulomatosis, and Churg-Strauss vasculitis), certain collagen- range from normal to rapidly decreasing over a few weeks orvascular diseases, and a variety of different types of GN. However, 1756 NephrologyForum: Goodpasture's syndrome

Table 1. Renal disease with pulmonary hemorrhage

Glomerulonephritis Goodpasture's syndrome Immune-complex glomeruloncphritis Acute silicoprotcinosis Glomerulonephritis with CHF D-penicillamine toxicity, trimellitic anhydride toxicity Vasculitis Polyarteritis nodosa Microscopic polyarteritis nodosa Wegener's granulomatosis Henoch-Schönlein purpura Mixed IgG-IgM Churg-Strauss allergic vasculitis Lymphoid granulomatosis Necrotizing sarcoid granulomatosis Behcet syndrome Hughes-Stovcn syndrome Hypocomplementemic urticaria Takayasu's arteritis Collagen vascular disease Systemic erythematosus Progressive systemic sclerosis Cardiovascular disease Advanced with superimposed CHF Mitral stenosis Pulmonary embolism with and underlying renal vein thrombosis Infection Legionnaire's disease Necrotizing pneumonitis Bronchitis Tuberculosis Fungus Lung abscess Bronchiectasis Malignancy with associated Blood dyscrasias Thrombotic thrombocytopenic purpura Hemolytie-uremic syndrome Idiopathic hemosiderosis

Fig. 3. Immunofluorescence microscopy illustrating (A) linear deposits of nodular densities and isolated segmental infiltrates do occur, as IgG along GBM and (B) fibrin within a crescent. seen in today's patient. Pulmonary function can be decreased, and episodes of pulmonary hemorrhage are associated with increased uptake of carbon monoxide, which can be used as a test of the must include infection, malignancy, andpulmonary hemorrhage and to document intercurrent episodes of any cause of pulmonary hemorrhage with decreased renal func-pulmonary hemorrhage [17]. Increased uptake occurs because of tion, as can occur with various antibiotics and unrelated acutebinding of carbon monoxide to extravasated blood within the lung renal failure. Pulmonary hemorrhage can precede the develop-and formation of carboxyhemoglobin in alveoli. ment of GN by several years, or it can develop after renal disease is manifest. The intensity of pulmonary hemorrhage provides few Laboratory findings clues to the presence of GPS and can range from blood-streaked The sine qua non for the diagnosis of GPS is demonstration of sputum to massive fatal pulmonary hemorrhage. Quite clearly,bound anti-GBM antibodies in the glomeruli of the kidneys. This temporal relationships exist between hemoptysis and environmen-finding usually is reflected by the presence of circulating anti- tal exposure, including various hydrocarbons, especially cigaretteGBM antibodies, most commonly of the IgG class, although smoking, and episodes of infection [15, 16]. Patients often com-occasionally IgA or 1gM [18]. The detection method for this plain of shortness of breath and cough, but usually not chest paincommon laboratory test is an extremely important consideration. or pleurisy, as occurs with pulmonary embolism. Although circulating anti-GBM antibodies are present in more Examination of the sputum can demonstrate hemosiderin-than 90% of patients with anti-GBM disease, indirect fluorescent containing , a nonspecific finding indicating pulmo-assays using kidneys from various species as substrate, including nary hemorrhage; chest radiographs reveal variable results. Alve-monkey kidney, can be falsely negative in 10% of cases or more. olar infiltrates spreading out from the hilum are common, butIn the present case, this method was used because it is less Nephrology Forum: Goodpasture's syndrome 1757

Table 2. Linear GBM deposits Table 3. Positive ANCA-associated conditions Anti-GBM disease Vaseulitis Goodpasture's syndrome Wegener's granulomatosis Idiopathic RPGN Churg-Strauss allergic vasculitis Membranous nephropathy with secondary anti-GBM disease Microscopic PAN ANCA +vaseulitis Anti-GBM disease Non-anti-GBM disease Crohn's disease Ulcerative colitis Renal allograft cx-vivo perfusion Felty's syndrome Focal sclerosis (rare) Sjogren's syndrome Polyarteritis Polymyositis Post-infectious glomerulonephritis (rare) Systemic lupus erythematosus Minimal-change disease (rare) Henoch-Schdnlein purpura Rheumatoid arthritis Ankylosing_spondylitis_(rare) - Hemodialysis Chronic liver disease HIV infection Other acute/chronic infection expensive than are radioimmunoassays (RIA) and ELISAs, which are more specific and have less than 5% false-negative rates. On the other hand, there are few false-positive results with these assays. Indirect fluorescence tests, as well as RIA and ELISA, arepressive therapy, but not pulse methylprednisolone or plasma falsely positive in probably 1% or less of positive tests. False-exchange, progressed to death or dialysis; only 10% experienced positive tests can arise from antibodies directed against othersome type of improvement [9]. The observation that anti-GBM constituents of type-IV collagen, from inexperience in interpreta-antibodies appear to cause the disease led to the use of plasma tion of indirect fluorescence, and from lack of proper controls.exchange as the appropriate therapeutic modality [22, 231. With When pulmonaiy hemorrhage, GN, and a negative RIA or ELISAthis type of treatment, approximately 50% of patients improved. assay are found, the chances of GPS are remote. However, patients with oligoanuria and those on dialysis uni- In my opinion, the diagnosis must be made on the basis of renalformly fail to respond to plasma exchange, pulse methyipred- histologic examination unless biopsy is contraindicated. We per-nisolone, or other therapy [9, 19, 23, 24]. Of note are rare reports form a renal biopsy on an emergency basis in any patient whoof patients with GPS who apparently recovered spontaneously might have GPS, regardless of the presence or absence ofeven after acute renal failure and the requirement for dialysis, and anti-GBM antibodies in the circulation. The rationale for thisthose in whom withdrawal of the offending agent, such as hair aggressive diagnostic approach involves the need for assessing thespray, was associated with recovery [25—27]. In general, however, degree of crescent involvement and the amount of sclerosis andthe consensus has been that the prognosis is extremely poor, but fibrosis at presentation, and to ascertain whether another diseaseperhaps improving because the defined spectrum of the disease is process is present [19]. Time is critical, because prognosis andincreasing (thus, embracing less ill patients), and because both response to therapy are closely tied to duration of disease andspecific and general medical therapy have improved. We should level of renal function prior to diagnosis and treatment. Theremember, however, that the grim figures on prognosis refer to presence of linear GBM deposits does not necessarily indicateGPS patients with the clinical presentation of RPGN. GPS (Table 2), and determination of whether antibodies in the Other factors also are important in the overall prognosis of circulation or on the GBM in vivo are specific for GBM is aGPS. A clear genetic influence exists. Patients who carry an necessary confirmation for the diagnosis of GPS. If circulatingHLA-DR W2, especially with HLA-B7, appear to have a more anti-GBM antibody is present, this is sufficient; if not, micro-malignant course of ON [23, 281. A high degree of crescent elution of renal tissue sections is necessary. Specific antibodiesformation (that is, more than 50%), the presence of tubulointer- eluted from glomeruli by indirect fluorescence fix to normalstitial disease with fibrosis, scarring, and glomerulosclerosis all human GBM, whereas antibodies in non-anti-GBM disease asso-bode ill for the patient [19, 29]. In patients who have a serum ciated with linear deposits do not fix to normal human GBM. ereatinine of 6 mg/dl, oliguria, or anuria, and in those requiring In summary, the differential diagnosis of GPS encompasses thedialysis, response to therapy is extremely poor and recovery rare. spectrum of any type of GN associated with any degree or cause of pulmonary hemorrhage. The broader definition of GPS utilized ANCA and anti-GBM antibodies in this discussion makes a renal biopsy imperative in virtually all Today's patient had circulating ANCA in a perinuelear pattern patients with any renal manifestations, including an active urinary(pANCA), which is associated with antibodies to myeloperoxi- sediment or abnormal urinary protein, to clarify the underlyingdase. Although numerous diseases are associated with ANCA pathology. The pathologic diagnosis has major importance in the(Table 3), we usually associate its presence with vasculitic syn- choice of appropriate therapy. dromes [301. We used to think that coexistent GPS and vasculitis were rare, and isolated reports of this association were considered IVatural course and prognosis interesting oddities [31, 32]. In 1989, however, O'Donoghue et al The clinical course of untreated, and even treated, GPS isreported three patients with ANCA-positive serum and anti-GBM bleak; this disease generally is associated with an extremely poordisease [33]. Since that time a number of additional patients have prognosis [10, 20, 21]. When we reviewed the natural course andbeen described, yielding a surprisingly high prevalence of ANCA prognosis of GPS in the mid-1980s, 89% of patients reported inwith GPS [34—36]. Approximately 30% of patients with circulating the literature who were treated with various types of immunosup-anti-GBM antibodies will have circulating ANCA at some time 1758 Nephro1oyForum: Goodpasture s syndrome

during the course of the disease. The ANCA can be positive prior Table 4. Events associated with the induction of anti-GBM disease to or after the development of anti-GBM disease. In patients with in humans anti-GBM disease, the pattern for thc ANCA is perinuclear in atInfections Influenza least three-fourths of the patients and cytoplasmic in the other Bacterial endocarditis one-quarter. The clinical course of disease in patients withToxin exposure Hydrocarbons, , drugs anti-GBM disease and a positive ANCA appears to be somewhatRenal injury , membranous ncphropathy Neoplasia Lymphomas, adenomas different than that in those with pure anti-GBM disease. First,Neoantigens Alport's syndrome only about one-half the "double-positive" patients require dialy- Endogenous GBM sis. In contradistinction to the scenario with GPS, a substantial Lung number of ANCA-positive patients have recovered sufficient renal Urine function to stop dialysis, although the exact percentage is not clear Choroid plexus [34, 351;itmight be as high as 30% to 50% judging from the small series that are available. Many ANCA-positive patients also have other vague systemic findings, including rash, fever, and myalgia,one with significant binding with Goodpasture's sera was a3 [41]. which are more suggestive of a vasculitie process than pureOther laboratories have reported that Goodpasture's sera, while anti-GBM disease, although such findings can occur with GPS.showing broad reactivity to various components of GBM, includ- Finally, there appears to be an inverse correlation betweening other NC1 domains, nonetheless have most reactivity to the anti-GBM titers, ANCA titers, and disease course; that is, patientsa3NCI domain [6—81. who have higher ANCA titers and lower anti-GBM titers tend to As with other autoimmune diseases, patients have a strong have a course that is more suggestive of vasculitis and respond tosusceptibility based on genetic background and, as I noted, certain therapy and even recover from dialysis; those with the highestHLA antigens are clearly associated with susceptibility to GPS anti-GBM titers pursue a more devastating course without returnand possibly to a worse phenotype. This association is similar to of renal function. Another clinical feature of "double-positive"the demonstration in various animal species of strain and species patients is the tendency for frequent relapses, seldom seen indifferences in susceptibility to disease [42]. Much evidence sup- patients with pure anti-GBM disease. However, informationports the concept that insult to the basement membrane or regarding this clinical entity is scant at present. Further studies arecross-reactivity with exogenous epitopes can initiate the process of needed to clarify the interrelationship between anti-GBM andautoimmunity resulting in the phenotype of GPS (Table 4). ANCA, and to determine what therapy is most appropriate andDifferent initiating events, such as infection, exposure to toxins, what factors determine the response to therapy. Because ANCArenal injury (including underlying glomerulopathy, as in today's is a relatively new laboratory test, it is not known how manypatient), ischemia, membranous nephropathy, and various types patients reported in the literature over the last several decadesof neoplasia could expose cryptic antigens by damaging the GBM. with anti-GBM disease had concomitant ANCA positivity andIn addition, urine contains antigens that conceivably could result how that affected the results of previous studies. in an autoimmune response if they gained access to the circula- tion. Finally, the model of most interest is that of Alport's familial Pathogenesis . These patients' GBMs are nonreactive with Goodpas- Understanding the pathogenesis of a disease is of paramountture's sera as opposed to normal GBM, and they lack the importance for developing specific therapy. The classic studies byto which Goodpasture's sera react [43, 44]. Many different abnor- Lerner, Glassock, and Dixon nearly 30 years ago were among themalities of a3(IV) collagen, which have been associated with first demonstrations of a GN in which the pathogenesis was knownAlport's syndrome, might result in incorrect assembly of the [37]. In those studies, nephritic kidneys obtained from patientsa3NCI domain in the GBM, thus accounting for the lack of the with GPS were acid-eluted and the eluted antibody purified. The Goodpasture's epitope. Transplantation in patients who have antibody then was injected intravenously into unilaterally ne-end-stage renal disease from Alport's syndrome has been associ- phrectomized monkeys. Microscopic examination of the GBMated with the development of circulating anti-GBM antibodies revealed intense staining for human IgG associated with fulmi-and their deposition in the graft, resulting in loss of the graft from nant GN, pulmonary hemorrhage, and progression to renal failureanti-GBM disease in a small number of cases [45—48]. Patients with proteinuria. The recent observations that GBM, lung, cho-who have this latter syndrome appear to be those most likely to be roid plexus, and basement membranes within the eye containreported in the literature, as the actual occurrence with conse- additional collagen chains other than the a1 and a2 typically foundquent graft loss may be small. In a combined series of 75 patients in type IV collagen, and documentation that most of the circulat-with Alport's disease who received renal transplants, 8 developed ing antibodies in patients with GPS are directed to the a3anti-GBM antibodies, and 2 patients lost their grafts [45—47]. non-cotlagenous (NCI) domain of type IV collagen, has addedRetransplantation in these 2 patients produced good graft sur- greatly to our understanding of the pathogenesis of GPS [7, 8, 38,vival, however. Thus, it seems obvious that some patients do 391.Althoughcontroversial, much evidence suggests that theindeed develop de-novo anti-GBM disease in the normal allograft circulating antibodies in patients with GPS are targeted mainly toin the setting of Alport's syndrome, but this is relatively uncom- the a3NC1 domain, with much of that reactivity to the last 36mon. Whether these patients were of a nonsusceptible MHC type amino acids of the chain; these have been termed "Goodpasture'sor whether other factors were involved is not clear. Patients with epitope" [40]. Further evidence of the specificity of these antibod-GPS have an exuberant cellular infiltrate with macrophages and ies for this domain has been derived from the studies by NeilsonT-cells and an intense secondary effector response, which appears and coworkers, who expressed recombinant proteins for the firstresponsible for the final phenotypic expression [discussed in detail five NC1 domains of type IV collagen and showed that the onlyin Refs. 23, 49—53]. Nephrology Fomm: Goodpasture's syndrome 1759

Experimental studies show that GBM contains antigens that 16 O =1 S can induce experimental autoimmune GN in several species, o =I&PE including sheep, goats, rats, rabbits, and mice [54—58]. The 14 • = DIALYSIS nephritogenic component that causes the proliferative GN ap- D = NON-DIALYSIS * = NO BIOPSY TISSUE pears to be present in dimers containing a3, a4, and a5, and not in a)12 those dimers containing a1 and a2 [57]. Recent studies from C10 Kalluri and colleagues show that dimers of NC1 type IV collagen . a) containing mostly a3 but also some components of a1, a2 and a4 0 can induce GN in rabbits and mice [57, 58]. The work from our E own laboratory and that of Sado shows that GBM collagen a) U . Ca 0 induces a model that appears to parallel GPS in every respect, S 0 complete with proteinuria, proliferative necrotizing GN with C 0 0 crescents, circulating and bound anti-GBM antibodies, and pul- W2 Do Do 0* monary hemorrhage [55, 56, 59, 601. It remains to be seen whether the nephritogenic 0 involved in GPS is the same as that in experimental models of 10 20 30 40 50 60 70 80 90 100 GPS. Although a3NCI-enriched dimers produce disease, and type % Crescents IV collagen lacking a3NC1 does not, immunization of rats withFig. 4. Influence of entty creatinine and percentage of crescents in patients Goodpasture's epitope is likewise unproductive of disease [57—59, treated with either immunosuppression (Ij) or immunosuppression plus 61]. Whether this latter outcome results from lack of conforma-plasma exchange (I& PE). Solid symbols represent patients proceeding to tional changes that are pathogenic, whether other modificationsdeath or dialysis. (*) indicates no biopsy or no glomeruli on biopsy. Used of the molecule are required for nephritogenicity, or whetherwith permission [64]. different effector mechanisms are involved with synthetic peptides rather than with native protein are among possibilities that remain to be evaluated. It is clear that patients with GPS have many I would like to address the issue of . The largest different circulating antibodies to a variety of components ofseries to date is that from Lockwood et al, who have treated more basement membrane, and that these antibodies can react withthan 100 patients with anti-GBM disease, most of whom have different peptides along the a3NCI chain. If the true nephrito-been treated with plasma exchange and immunosuppression [10, genic peptides can be identified, then direct intervention in GPS23, 24, 651. Six of seven patients with normal renal function who is feasible. However, patients and animals alike can demonstratewere treated all improved, and one patient with normal renal circulating and bound anti-GBM antibody without disease, andfunction improved without treatment. Three-fourths of 20 pa- patients who had GPS originally can receive transplants withouttients with serum creatinine levels of 7 mgldl improved with developing GPS or even GP disease [62, 63]. Why these differ-plasma exchange, but only one of 12 with creatinine levels > 7 ences occur and what accounts for them are intriguing questions,mg/dl showed improvement. No improvement was observed in the answers to which will further refine our ability to modelany of the 58 patients who were on dialysis. specific therapies for this devastating clinical syndrome. Plasma exchange effectively removes circulating antibodies directed to GBM [22, 64]. Standard therapy consists of 14 Treatment exchanges of 4 liters each over two weeks, combined with pred- Pulmonary hemorrhage associated with GPS usually respondsnisone and immunosuppressive drugs such as rapidly to pulse methylprednisolone or to plasma exchange [9, 23,or . This approach diminishes circulating antibody 64]. In some patients, neither modality is of benefit; we have hadlevels without rebound after cessation of plasma exchange as long a few patients with intractable pulmonary hemorrhage who haveas immunosuppressive therapy is continued. However, there is no died because plasma exchange, pulse methyiprednisolone, andgood correlation between circulating antibodies at the time of cytotoxic therapy all were ineffective. presentation and the histologic severity of GN, nor does a good As I said earlier, conventional treatment—defined as prednisonecorrelation exist between a decrease in antibody titers and re- and other types of immunosuppression in standard doses—hassponse to therapy in the patients who do not require dialysis [22, produced little beneficial effect. The presence of circulating66]. Only one prospective randomized controlled study has been anti-GBM antibodies has served as an obvious rationale foraccomplished. In this study, Johnson and coworkers compared the removal of these antibodies by plasmapheresis or immunoglobu-effects of therapy with pulse methyiprednisolone immunosuppres- lin-adsorbent columns. Although the literature contains limitedsion alone to immunosuppression combined with plasma ex- information about patients who have anti-GBM disease withchange (Fig. 4) [64]. Although antibody levels were reduced to a normal kidneys or minimal renal disease, it seem obvious that thismuch greater extent, as one would expect with plasma exchange, group of patients will have a good prognosis with either nothere was no significant difference in the clinical outcome between therapy, withdrawal of the offending agent, or standard immuno-the two groups. Analysis of clinicopathologic findings at study suppressive therapy [12, 13, 261. In the setting of RPGN or activeentry suggested that the percentage of crescents on initial renal crescentic involvement on renal biopsy, however, aggressive ther-biopsy and the entry serum creatinine concentration correlated apy is required in those patients with the potential for benefit. Inbetter with outcome than did the type of therapy utilized. The contrast, patients who have the poor prognostic findings I men-authors noted that the patients with a lower percentage of tioned are unlikely to respond and should be spared the risks ofcrescent formation and well-preserved renal function did better aggressive therapy. with either type of treatment than did patients with severe 1760 Nephrology Forum: Goodpasture's syndrome

Non-Px Px

0/36 0/5 1*• U®®AA A **• I®AA A * ••®A A > *• ®A AA A * • A A

50% Crescents

Non-Px Px 11/14 11/11 A •0 0 * A 0 *

Serum creatinine 5 mg!dl >

Conventional! I m mu nosu ppression Series N pulse therapy and plasma exchange Briggs [66] 19 Johnson [64] 17 r pulse Simpson [68] 19 0 Bolton [19] 17 ll pulse

*Fajled initial pulse—came off dialysis @4 mc., serum creatinine 4.0 mg/dl Solid — treatment failure Open — Response to therapy Px — Plasma exchange

Fig. 5. Influence of ently serum creatinine and percentage of crescents in 4 series with individually analysable patients treated with plasmapheresis or other therapy. Used with permission [67]. crescentic involvement and impaired GFR. Although this is thepulse methylprednisolone) [91. Patients treated with plasma ex- only prospective randomized trial that has been done, it had onlychange received variable numbers of exchanges but also received 17 patients. Our own experience and that of others has suggestedprednisone and cyclophosphamide. The individual patients from that patients with mild anti-GBM disease may well respond tothe four series are differentiated by symbols. As Figure 5illus- therapies other than plasma exchange [52, 67]. Figure 5graphi- trates, patients with anti-GBM disease generally segregate at cally displays the results of four series in which adequate infor-entry into the medical system into those who have a serum mation allowed assessment in individual patients of the impact ofcreatinine of 5 mg/dland <50% crescentsor those who have serum creatinine and percentage of crescent involvement [19, 64,a greater involvement of glomeruli, with > 50%crescentsand a 66, 68]. Patients were treated with plasma exchange, pulse meth-serum creatinine > 5mgldl.In the former group, 78% of patients ylprednisolone, or conventional therapy (defined as no therapy ortreated with conventional therapy or pulse methylprednisolone any type of immunosuppression other than plasma exchange orwere stable or improved (11/14) compared with 11 patients Nephrology Fomm: Goodpasture's syndrome 1761 treated with plasma exchange, all of whom were stable or im- Table 5. Therapeutic protocols proved. Conversely, in the patients with serum creatinine levels ofA. Pulse methylprednisolone > 5 mg/dl or > 50%crescents,none of the 36 patients treated Volume repletion ascertained with any type of immunosuppression alone showed any improve- No diuretics 3 hours before pulse or 24 hours after ment, nor did any of the 5 patients treated with plasma exchange. 30 mg/kg methylprednisolone given IV over 20 minutes every These findings are consistent with the large series from Lockwood other day for 3 doses Single dose not to exceed 3 g in which these latter types of patients showed no response [231. Monitor blood pressure during and 4 hours after infusion While the recommendation always has been that patients with B. Oral prednisone, given every other day anti-GBM disease should be treated first and foremost with Dose" (mg/kg) Duration/months of therapy' plasma exchange, several issues need to be considered. Patients 2.0 0.5 1.75 1.0 with lesser degrees of crescentic involvement and with less 1.50 3.0 advanced renal failure appear to do very well without plasma 1.25 6.0 exchange. In patients who have GPS and who receive transplants 1.00 6.0 [62, 63, 69], anti-GBM deposits recurred in approximately one- 0.75 6.0 half of them but only one-third of the patients with anti-GBM 0.50 6.0 0.25 6.0 antibodies lost their transplants because of recurrent disease. All 0.125 12.0 those patients were, of course, receiving immunosuppressive 0.0625 12.0 therapy for their allograft and were temporally distant from the C. Cyclophosphamide 2.0 mg/kg daily for 3 months original initiating process. In addition, in patients with Alport's 1.5 mg/kg daily for 3 months syndrome who are known to have an increased risk of developing 1.0 mg/kg daily for 3 months anti-GBM disease, the de-novo development of anti-GBM disease 0.5 mg/kg daily for 3 months associated with linear deposits along the GBM on neo-antigens in Decrease dose 50% for Ccr 10 mg/mm" the allograft is uncommonly associated with loss of the transplant Hold dose if WBC 3500/mm3, or platelets 100,000/mm3 D. Plasma exchange [45—47]. Finally, plasma exchange removes circulating antibodies, 4 liter exchanges 5/7 days or every other day X 14 exchanges which do not correlate well with the clinical course, but it also minimum induces a state of immunosuppression, causes "decomplementa- Replacement with 5% normal human serum albumin tion," and decreases fibrinogenic products. Substances that might Fresh-frozen plasma if bleeding problems have immunoregulatory activities, such as anti-idiotypic antibod- Always be certain cyclophosphamide is used when patients receive ies, are removed as well. We have in fact seen several patients with plasma exchange (immunoglobulin rebound suppression) - minimal renal dysfunction who were treated with plasma ex- a Patients60years of age should receive 75% of oral prednisone dose change and who appeared to have an acceleration of their diseaseon alternate days; for very obese patients, use ideal body weight. hIffull remission of proteinuria, normal function for one month, that resulted in an eventual need for dialysis and transplantation.decrease to next dose step. These observations suggest that the question of appropriate Ccr =creatinineclearance. therapy for anti-GBM disease is still not entirely settled. Nonetheless, it is necessary to have a therapeutic stratagem for approaching the patient with GPS in the clinic. Table 5describes our therapeutic protocols, and the algorithm in Figure 6 presentsargument for plasma replacement rather than albumin in patients our approach to the diagnosis and therapy of GPS. The corner-with ANCA, because plasma can have beneficial effects even in stones in decision-making are the serum ANCA studies, the renalvasculitic patients refractory to standard vasculitis therapy [73]. In biopsy, the anti-GBM assay, and the patient's renal function. Inall cases, treatment is individualized by clinical judgment in an ANCA-negative patients with serum creatinine levels 6 mg/dlattempt to provide the most effective treatment while not putting and 50% crescents, we generally use plasma exchange andthe patient at undue risk from therapy. These considerations immunosuppression. For patients with > 50% crescents and > 6tempered the treatment decision for the patient presented here. mgldl serum creatinine, oligoanuria, or those on dialysis, we treat Many types of therapy not discussed here have been tried in pulmonary hemorrhage but utilize only a short course of plasmaGPS without success. Data from experimental animals suggest exchange and immunosuppression or none at all. If the ANCA isthat a variety of new agents may be beneficial in GPS. These positive, we treat for vasculitis with or without plasma exchange.include IL-i receptor antagonists, TNFa receptor protein, anti- For non-dialysis-dependent patients with high-titer anti-GBMbodies to various cell-surface adhesion molecules, deoxyspergua- antibodies, we use plasma exchange and immunosuppression.un, and immunoregulating proteins such as CTLA4-Ig [74—77]. Although plasma exchange appears of no benefit for dialysis- Removal of anti-GBM antibodies by immunosorbent columns has dependent patients with GPS, there is evidence that it is useful ifyielded no benefit [78]. Perhaps one of the most exciting potential vasculitis is the cause of dialysis dependence [701. Therefore wetherapies is the use of immunosorbent chromatography using the use plasma exchange and immunosuppression for dialysis-depen-Goodpasture epitope to remove circulating antibodies. Prelimi- dent, "double-positive" patients. For low-titer anti-GBM/ANCA-nary evidence from Boutaud et al demonstrates that anti-GBM positive patients, we lean more toward using therapy directedantibodies can be absorbed from the serum of patients with GPS against vasculitis, that is, pulse methylprednisolone or oral pred-using recombinant a3(IV) NC1 domain [79]. nisone and cyclophosphamide, although others use intravenous Finally, as in the case of the anti-GBM assay, additional cyclophosphamide [71, 72]. We might be swayed to add plasma-important considerations these days include the cost of therapy. pheresis if an RPGN course or a highly active histologic lesionAt our institution, a 14-day course of plasma exchange is approx- were present. When plasma exchange is used, one could make animately $34,000 plus the cost of hospitalization. The cost of pulse 1762 NephrologyForum: Goodpasture's syndrome

History & physical examination

Hematologic, chemical and serologic studies

Renal biopsy Other

Crescentic Other glomerulonephritis

Anti-GBM antibodies

Serum creatinine

6 mg/dl/ >6 mg/dl 50% crescents > 50% crescents

Plasma exchange -Supportive care Prednisone prednisone -Pulse steroids cyclophosphamide cyclophosphamide or plasma exchange for pulmonary hemorrhage -Transplantation

Fig. 6. Algorithmic approach to diagnosis and therapy of patients with pulmonaty renal syndrome.

methyiprednisolone is $156. However, since the cost of dialysis iswith Alport's syndrome who has received a transplant do not eat about $20,000/year, it may be cost effective to use plasmapheresisup the glomerular basement membrane? in all patients with a serum creatinine level < 5—6 mg/dl. DR. BOLTON: That is a terrific question. I do not know the Appropriately conducted prospective trials obviously are requiredanswer. The antibody specificity by immunoblot appears to be the [80]. I believe that the diagnostic and therapeutic approachsame. Whether the difference is related to transplant immunosup- provided here represents a reasonable and cost-conscious regi-pression or different epitope specificities in the de-novo glomer- men until parameters can be delineated that predict whichulonephritis is not known. patients will develop the most aggressive GPS requiring the most DR. AJAY SINGH (Division of Nephroloçy, New England Medical aggressive treatment, and what that treatment should be. Center, Boston): My first question is about the nature of the antibody response in patients with Goodpasture's syndrome. As Questions and answers you know, McPhaul et al, in their classic study [141, and others I'm DR. JOHN T. HARRINGTON (Dean ad interim, Tufts University sure, have documented that IgG is the predominant isotype in School of Medicine, Boston, Massachusetts): Why does anti-GBMpatients with Goodpasture's. However, I recall that some studies antibody cause disease in patients with "real" Goodpasture'salso have suggested a unique subclass distribution among patients disease, whereas the same anti-GBM antibodies in the patientwith Goodpasture's syndrome as compared to sera from normal Nephrology Forum: Goodpasture's syndrome 1763

subjects. This would suggest a regulatory defect in the immunesuggests that there are differences even though the amino acids response. Could you comment on this? Further, do you know ofare the same. studies that have explored whether certain idiotypes are more DR. HARRINGTON: I have a followup question regarding the frequently expressed in the anti-GBM antibody response? same amino acid epitope but at a clinical level. Smoking, hair DR. BOLTON: Segelmark examined antigen restriction and IgGspray, and other pulmonary toxins frequently are invoked as subclass of anti-GBM antibodies using purified monomers of a1,stimuli to the production of Goodpasture's syndrome. If that is a2, a3, and a4 chains. There was a preference for IgG 1 isotypestrue, why does it happen so extraordinarily infrequently? in Goodpasture's syndrome but a subset, mostly females, also had DR. BOLTON: We are beginning to see a wide spectrum of high-titer IgG 4 antibodies [18]. Lewis et al also have noted aanti-GBM disease ranging from patients who are entirely asymp- relative absence of IgG 3 isotype and anti-GBM disease and largetomatic to those who have RPGN. It is not known why this amounts of IgG 4, a pattern of distribution different from normalspectrum exists. It is probably related to the intensity of exposure serum components [81]. Rees et al have reviewed the clinical andto the antigen, or to the epitopes involved, or to genetically experimental data in great detail regarding idiotype responses andinfluenced immune responsiveness. immune regulation [23]. DR. ANDREW J. KING (Division of Nephrology, New England DR. SINGH: As you know, David Isenberg and Yehuda Shoen-Medical Center): Does Goodpasture's syndrome originate in the feld and others have reported the presence of certain idio-kidney? If so, what is the sequence of events? Specifically, is there types—in particular 16/6—shared among different patients withrelease of collagen or some other process that initiates the lupus [82, 83]. Indeed, with respect to the 16/6 idiotype, Shoenfelddisease? has reported that when antibodies expressing this idiotype are DR. BOLTON: We think that it must originate from kidneys, but I do not know that anybody has really shown that. Ray Steblay injected into normal laboratory mice, they develop disease [84]. Has this sort of work been performed in Goodpasture's syn-showed years ago that you can cause Goodpasture's syndrome in drome? animals by immunizing with lung basement membrane [88]. The DR. BOLTON: Several animal models have been used to studylist of things that cause release of basement membrane constitu- these questions and are reviewed in the excellent chapter by Reesents includes a wide range, from cortical to membranous that I mentioned [23]. nephropathy to other underlying disease. There are all sorts of DR. SINGH: My other question is directed towards the geneticsinsults in the kidney that have been associated with it. Not so in of Goodpasture's syndrome. A close association between DR2the lungs. Maybe that points to the kidney as being the primary and Goodpasture's syndrome has been reported in the literaturesite. But I don't know that for sure. DR. KING: Frequently these patients present Friday evening in [15, 85]. However, as you know, the Goodpasture's antigenthe emergency room. We rely on ANCA and indirect immuno- (COL4A5) has been cloned, and maps to the q36 to q37 site on fluorescence as our guidelines as to whether the patient has this chromosome 2 [86], whereas the HLA antigen, DR2, maps to type of disease. Why do you think the renal biopsy is essential in chromosome 6. These observations would suggest a nonstructural the management of patients who are not dialysis dependent? Do explanation for the relationship of DR2 with Goodpasture's. you ever rely on these serologic markers? What do you think might be the association? DR. BOLTON: In the situation that you describe, in which the DR. BOLTON: T agree. Presumably immune responsiveness to the patient arrives at off hours, we go ahead and treat if we cannot get Goodpasture's antigen is linked to the DR2, that is, peptidethe pathology. We use clinical judgment and give pulse methyl- processing and presentation to T-cell receptors. and wait until we get the definitive answer. We use DR. NIcoLAos E. MADIAS (Chief Divison of Nephrology, New the biopsy because of the inability of the clinical course to reveal England Medical Center): My question concerns the Goodpas-the degree of crescent formation and cellularity, and thus revers- ture's epitope. Can you expand on what aspects of the nature andibility of crescents, and the degree of fibrosis and scarring. If there suprastructure of Goodpasture's epitope might account for itsis severe sclerosis in the glomeruli or interstitium, I would tend to cryptic properties? be much less aggressive in terms of treatment and have a much DR. BOLTON: The epitope being bound by Goodpasture's serum lower threshold for stopping. is sequestered inside the hexamer, which is made up of the DR. HARRINGTON: How do you treat the patient who is anti- globular regions of the various noncollagenous domains. One canGBM positive? The data you showed revealed a strong correlation increase the binding between the noncollagenous domain andbetween a serum creatinine of less than 5 mg/dl and a percentage Goodpasture's antibody up to 50-fold by revealing the epitope;of crescents of less than 50%, and vice versa. In view of those data this can be done by treating the hexamer with acid which unfoldsand the low cost of measuring the serum creatinine, versus a renal it. Binding is also diminished by manipulations that affect tertiarybiopsy, why don't we believe the serum creatinine and act on it? structure, such as reduction and alkylation, digestion with trypsin DR. B0LT0N: In today's cost-conscious environment, we might and cyanogen bromide, and disruption of lysines by acetylation.be headed in this direction, I feel more secure in knowing how Thus, the antigen is cryptic or hidden and discontinuous. much sclerosis is present to tell the patient what I think the DR. MIAs: Is the stoichiometry and assembly of the subunitsprognosis is going to be. I cannot tell the patient as much about of the epitope identical at the various sites where Goodpasture'sprognosis by looking at the serum creatinine. epitope exists? DR. HARRINGTON: Do you mean that if the serum creatinine is DR.BOLTON: Idon't know. I suspect that it is not. BasementI or 6 mg/dl, you can't predict the outcome? membrane in the lung and kidney have different dimer/monomer DR. BOLTON: As Figure 5 shows, histology is very accurate in ratios for a3, with kidney being mostly dimers and some mono-predicting prognosis. The numbers are too small for serum mer, but lung being mostly monomer and some dimer [87]. Thiscreatinine <5 mg/dI and < 50% crescents to know whether serum 1764 NephrologyForum: Goodpasturev syndrome creatinine alone is predictive. If the serum creatinine is > 6 mg/dl, DR. MADIAS: Do any of these patients have evidence of systemic however, there is probably much less chance of the patientvasculitis? responding. DR. B0L1oN: They have many vague manifestations suggestive DR.MADIAS:I would like to return to Dr. Harrington's questionof vasculitis. Histologic lesions of vasculitis are uncommon, how- about Alport's syndrome. As you mentioned, most cases ofever. X-linked Alport's syndrome have defects of the a5(IV) chain, DR. MAD!AS: About a year ago in a Nephrology Forum, Dr. which can affect the cx3(IV) chain [89]. I would have expected that Robert Atkins discussed the role of , specifically IL-i, in most anti-GBM antibodies post grafting would be anti-5. Do thethe pathogenesis of the entity and presented data on the beneficial few patients who develop aggressive anti-GBM disease haveeffects of the IL-l receptor antagonist (IL-Ira) in a rat model of predominantly anti-cs3 antibodies as opposed to anti-cs3, and is itaccelerated anti-GBM disease [90]. He concluded his Forum by known whether their genetic defect is different? Is there asaying that he and his colleagues were setting up an international relationship between aggressive anti-GBM disease and pre-exist-multicenter trial to study the use of IL-ira as an adjunct to ing rejection episodes? Under what circumstances should oneconventional immunosuppression in patients with RPGN includ- monitor levels of anti-GBM antibodies? ing anti-GBM disease. Do you know whether this trial is in DR. BOLTON: In the one case examined, the de-novo antibodies progress? were to a3 and not a5 or other chains [44]. 1 am not aware of DR. BOLTON: I talked to Bob at the meetings this past month. analysis of genetic defects in those with and without de-novoHe did not say anything about it going forward. I do not know disease, but that is an interesting question. I am also not aware ofwhat the status is. an association with previous rejection, but the numbers are very DR. MADtAS: You listed a number of futuristic therapies. Do small. I do not believe prospective monitoring of anti-GBMyou think gene therapy will be included among them in an effort antibodies is warranted. to alter production? DR.KING:Many of the patients who present to us are dialysis DR. BOLTON: This is certainly possible, certainly futuristic, and dependent. Do we treat for possible pulmonary hemorrhage? Doraises many questions. How do you target the gene to its site of you believe in screening patients for pulmonary hemorrhage byaction? How do you control it? What are the long-term effects? using carbon monoxide diffusion capacity and other modalities? How does it perturb other regulatory processes? What are the DR. BOLTON: We do not routinely do that. if the patient doesunexpected consequences? The leaps between theories, genes, not have any kind of clinical pulmonary symptoms, we do notanimal models, and the bedside are significant. Gene therapy is an screen or treat. appealing approach to the control of , but from a DR.SINGH:Work from Kalluri and colleagues presented inpractical point we need much more information. abstract form at the recent American Society of Nephrology meeting suggests that there is variable phenotypic expression of Reprint requests to: Dr. W. K. Bolton, Chief Division of Nephrology, anti-GBM disease in murine models [58]. In this regard, humansUniversity of Virginia Health Sciences Center, Box 133, Charlottesville, also demonstrate phenotypic variability, from anti-GBM nephritisVirginia, 22908, USA without pulmonary abnormalities to the full-blown Goodpasture's syndrome [3]. Could you comment on the potential role of genetic Acknowledgment factors in modulating the clinical expression of anti-GBM dis- The author thanks C.V. Cook for secretarial assistance. This work was ease? supported in part by U.S. Public Health Service grant DK44107 from the DR. BouroN: There are differences in the clinical phenotypeNational Institute of and Digestive and Kidney Diseases. that occur based on the underlying immune response. This response is very complex in terms of the type of cytokine response, References type and degree of antibody and cellular immune response, and other effector systems. Presumably genetic influence in all these 1. GOODPASTURE EW: The significance of certain pulmonary lesions in effector systems dictates the final clinical expression. relation to the etiology of influenza. Am J Med Sci 158:863—870, 1919 DR. HARRINGTON: don't understand the patients who are 2. STANTON MC, TANGC JD: Goodpasture's syndrome (pulmonary I haemorrhage associated with glomerulonephritis). Aust Ann Med double positive, that is, ANCA and anti-GBM positive. Is their 7:132—144, 1958 disease closer to Goodpasture's or Wegener's? Do they have 3. 1-IOLDSWORTI-I SR, Boven N, ThoMsoNNM,ATKINS RC: The clinical double disease or is this one disease? Does it make a difference in spectrum of acute glomcrulonephritis and lung haemorrhage (Good- clinical outcome whether they are P-ANCA versus C-ANCA pasture's syndrome). Q J Med 55:75—86, 1985 4. COHEN AH, GLASSOCK RJ: Anti-GBM glomerulonephritis including positive? Goodpasturc's syndrome, in Renal Pathology, edited by TISHER CC, DR. BOLTON: I really do not know. A few years ago ANCA BRENNLRBW, Philadelphia, Lippincott, 1989, p 494 positivity with anti-GBM disease was considered rare. Flowevcr, 5. HUDSON BG: Anti-type TV collagen diseases. The immunologic basis now there are a number of papers indicating 30% association. of renal disease: Paradigms for the 21st century: TheAmerican Society Most arc P-ANCA (75%) and titers of ANCA and anti-GBM of Nephrologyc Advances in Basic Science Conference, San Diego, CA, 1995 antibodies tend to be inversely related. I am not convinced that 6. J0IINAN5sON C, HELLMARK T, WIESLANDIR J: One major epitope in ANCA causes disease, but it could. It is appealing to think that Goodpasture's syndrome. .1 Am Soc Nephrol 4:608, 1993 these patients have vasculitis that damages the kidney, which 7. KEFALIDES NA, OHNO N, WILSON CB: Heterogeneity of antibodies in releases basement membrane and then secondary anti-GBM reacting with type IV collagen. Kidney mt antibodies are formed. I do not know whether these secondary 43:85—93, 1993 8. MAISUKIJRA II, BUTKOWSKI RJ, FIsh AJ: The Goodpasture antigen: antibodies are pathogenic. Thus, some might be closer to Wege- Common epitopes in the globular domains of collagen IV. Nephron ner's, while others are more like Goodpasture's syndrome. 64:532—539, 1993 Nephrolo Forum: Goodpasture's syndrome 1765

9. BOLTON WK: The role of high dose steroids in nephritic syndromes: phil eytoplasmic antibodies complicating anti-glomerular basement The case for aggressive use, in Controversies in Nephrology and membrane disease. C/in Nephrol 32:25 1—255, 1989 Hypertension, edited by NARIN5 RG, New York, Churchill-Living- 34. JAYNE DRW, MARSHALL PD, JONES SJ, LocKwooD CM: Autoanti- stone, 1984, p 421 bodies to GBM and neutrophil cytoplasm in rapidly progressive 10. SAVAGECOS,PUSEYCD,BOWMAN C, REE5 AJ, LOCKWOOD CM: glomerulonephritis. Kidney In! 37:965—970, 1990 Antiglomerular basement membrane antibody mediated in the British 35. BOSCH X, MIRAPEIX E, FONT J, BORRELLAS X, RODRIGUEZ R, Isles 1980—4. Br Med J 292:301—304, 1986 LoPEz-SoTo A, INGELMO M, REVERT L: Prognostic implication of 11. TEAGUE CA, DOAK PB, SIMPSON Ii, RAINER SF, HERD5ON PB: anti-neutrophil cytoplasmic with myeloperoxidase Goodpasture's syndrome: An analysis of 29 cases. Kidney mt 13:492— specificity in anti-glomerular basement membrane disease. C/in Neph- 504, 1978 rol 36:107—113, 1991 12. BAILEY RR, SIMPSON IJ, LYNN KL, NEALE TJ, DOAK PB, MCGIVEN 36. SHORT AK, ESNAULT VL, LOCKWOOD CM: ANCA and anti-GBM AR: Goodpasture's syndrome with normal renal function. Clin Neph- antibodies in RPGN. Adv Exp Med Biol 336:441—444, 1993 rot 15:211—215, 1981 37. LERNER RA, GLASSOCK RJ, DIxoN FJ: The role of anti-glomerular 13. ZIMMERMAN SW, VARANASI UR, HOFF B: Goodpasture's syndrome basement membrane antibody in the pathogenesis of human glomer- with normal renal function. Am J Med 66:163—171, 1979 ulonephritis. J Exp Med 126:989—1004, 1967 14. MCPitAuI. JJ, DIXON FJ: Characterization of human anti-glomerular 38. HUDSON BG, WEISLANDER J, WISDOM BJ, NOELKEN ME: Goodpas- basement membrane antibodies eluted from glomerulonephritie kid- ture syndrome: Molecular architecture and function of basement neys. J C/in Invest 49:308—317, 1990 membrane antigen. Lab Invest 61:256—269, 1989 15. DONAGHY M, REES AJ: Cigarette smoking and lung haemorrhage in 39. BUTKOWSKI RI, LANGEVEIDJPM,WIESLANDER J, HAMILTON J, HUD- glomerulonephritis caused by autoantibodies to glomerular basement SON BG: Localization of the Goodpasture epitope to a novel chain of membrane. Lancet 2:1390—1392, 1983 basement membrane collagen. J Biol Chem 262:7874—7877, 1987 16. WHITWORTH JA, MOREL-MAROGER L, MIGNON F, RICHET G: The 40. KALLURI R, GUNWAR 5, REEDERS ST, MORRISON KC, MARIYAMA M, significance of extracapillary proliferation. Nephron 16:1—19, 1976 EBNER KE, NOELKEN ME, HUDSON BG: Goodpasture syndrome. 17. EWAN PW, JONES HA, RHODES CG, HUGHES JMB: Detection of Localization of the epitope for the autoantibodies to the earboxyl- intrapulmonary hemorrhage with carbon monoxide uptake: Applica- terminal region of the a3(IV) chain of basement membrane collagen. tion in Goodpasture's syndrome. N Engl J Med 295:1391—1396, 1976 J Biol Chem 266:24018—24024, 1991 18. SEGELMARK M,BUTKOWSKI R, WIESI.ANDER J: Antigen restriction and 41. NEILSON EG, K.ALLURI R, SUN MJ, GUNWAR S, DANOFF T, MARIYAMA IgG subclasses among anti-GBM autoantibodies. Nephrol Dial Trans- M, MYERS JC, REEDERS ST, HUDSON BG: Specificity of Goodpasture plant 5:991—996, 1990 autoantibodies for the recombinant noneollagenous domains of hu- 19. BO!:'oN WK, STURGILL BC: Methylprednisolone therapy for acute man type IV collagen. J Biol Chem 268:8402—8405, 1993 ereseentic rapidly progressive glomerulonephritis. Am J Nephrol 42. SADO Y, NAITO 1, AKITA M, OKIGAKI T: Strain specific responses of 9:368—375, 1989 inbred rats on the severity of experimental autoimmune glomerulo- 20. WALKER JF, WATSON AJ, GARRETt P, CRONIN CJ, BEOGII B, DoNo- nephritis. J C/in Lab Immunol 19:193—199, 1986 HOE JF, CARMODY M, O'DWYER WF: Goodpasture's syndrome—7 43. MCCOY RC, JOHNSON HK, STONE WJ, WILSON CB: Absence of years experience of two Dublin renal units. IrMedJ75:328—333, 1982 21. STRUTZ F, NEILSON EG: The role of lymphocytes in the progression of nephritogenic GBM antigen(s) in some patients with hereditary interstitial disease. Kidney mt 45:S105—S1 10, 1994 nephritis. Kidney Int 21:642—652, 1982 22. PETERS DK, REES AJ, LocKwooD CM, PUSEY CD: Treatment and 44. HUDSON BG, KALLURI R, GUNWAR 5, WEBER M, BALLESTER F. HUDSON JK, NOELKEN ME, SARRAS M, RICHARDSON WR, SAUS J. prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc 14:513—521, 1982 ABRAHAMSON DR, GLICK AD, HARALSON MA, HELDERMAN JH, 23. REES AJ, LocKwoot CM: Antiglomerular basement membrane an- STONE WJ, JACOBSON HR: The pathogenesis of involves type IV collagen molecules containing a3(IV) chain: Evi- tibody-mediated nephritis, in Diseases of the Kidney, edited by dence from anti-GBM nephritis after renal transplantation. Kidney mt SCHRIER RW, GOTrSCHALK CW, Boston, Little, Brown, 1988, p 2091 24. LOCKWOOD CM, PEARSON TA, REES AJ, EVANS DJ, PETERS DK: 42:179—187, 1992 Immunosuppression and plasma exchange in the treatment of Good- 45. MILlINER DS, PIERIDES AM, HOLLEY KE: Renal transplantation in pasture's syndrome. Lancet 1:711—715, 1976 Alport's syndrome. Mayo C/in Proc 57:35—43, 1982 25. COHEN LH, WILSON CB, FREEMAN RM: Goodpasture syndrome: 46. GOBEL J, OLBRICHT J, OFFNER G, HELMCHEN U, REPP H, KOCH KM. Recovery after severe renal insufficiency. Arch Intern Med 136:835— FREI U: Kidney transplantation in Alport's syndrome: Long term 837, 1976 outcome and allograft anti-GBM nephritis. Kidney In! 38:299—304. 26. BERNIS F, HAMELS J, QUOIDBACH A, MAHIEU P, BOUVY P: Remission 1992 of Goodpasture's syndrome after withdrawal of an unusual toxin. C/in 47. QUERIN 5, NOEL LH, GRUNFELD JP, DROZ D, MATHIEU F, BERGER J, Nephrol 23:312—317, 1985 KREIS H: Linear glomerular IgG fixation in renal allografts: incidence 27. STRAUCII BS, CIARNEY A, DOCTOROUFF 5, KASHGARIAN M: Good- and significance in Alport's sydrome. C/in Nephrol 25:134—140, 1986 pasture's syndrome with recovery after renal failure. JAIVL4 229:444, 48. SHAH B, FIRST MR, MENDOZA NC, CLYNE DH, ALEXANDER 1W, 1974 WIESS MA: Alport's Syndrome: Risk of glomerulonephritis induced 28. REES AJ, PETERS OK, COMI'SION DAS, BATCHELOR JR Strong by anti-glomerular-basement-membrane antibody after renal trans- association between 1-ILA DRW2 and antibody mediated Goodpas- plantation. Nephron 50:34—38, 1988 ture's syndrome. Lance! 1:966—968, 1978 49. Borroa WK, INNEs DJ, STURGILL BC, KAISER DL: T-cells and 29. GLASSOCK RJ: Clinieo-pathologie spectrum and therapeutic strategies maerophages in rapidly progressive glomerulonephritis: Clinicopath- in "rapidly progressive" glomerulonephritis. Proc Dialysis Transplant ologic correlations. Kidney Int 32:869—876, 1987 Forum 5:109—116, 1975 50. SALANT DJ: Nephrology Forum: Immunopathogenesis of creseentie 30. WILKOWSKI MJ, BOLTON WK: Autoantihodies and other autoimmune glomerulonephritis and lung purpura. Kidney In! 32:408—425, 1987 serologic abnormalities in dialysis patients. Scmin Dial 8:226—231, 51. B0I:IoN WK: Mechanisms of glomerular injury: Injury mediated by 1995 sensitized lymphocytes. Semin Nephrol 11:285—293, 1991 31. Wt MJ, RAJARAM R, SHELP WD, BEIRNE GJ, BURKHOLDER PM: 52. COUSER WG: Rapidly progressive glomerulonephritis: Classification, Vasculitis in Goodpasture's syndrome. Arch Paihol Lab Med 104:300— pathogenetic mechanisms, and therapy. Am J Kidney Dis 11:449—464, 302, 1980 1988 32. WAHI.STL,BoNsIB SM, SCHUSTER VL: Coexistent Wegener's granu- 53. MAIN 1W, NIKOI.IC-PAIERSON Dl, ATKINS RC: T cells and macro- lomatosis and anti-glomerular basement membrane disease. Human phages and their role in renal injury. Semin Nephrol 12:395—407, 1992 Pat/lot 18:202—205, 1987 54. STEBLAY RW: Preliminary evidence for the production of nephritis by 33. O'DONOGHUE DJ, SI IORT CD, BluNrI II,IY C, LAWI.ER W, BALLARDIE an autoimmune mechanism, in Inflammation and Diseases of Connec- FW: Sequential development of and anti-neutro- tive Tissue, edited by MILLS LC, MOYER JH, Saunders, 1961, p 272 1766 NephrologyForum: Goodpasture's syndrome

55. BOLTON WK, MAY WJ, STURGILL BC: Proliferative glomerulonephri- 74. NIKOLIC-PATERSON Di, LAN HY, HILL PA, VANNICE JL, ATKINS RC: tis in rats: A model for autoimmune glomerulonephritis in humans. Suppression of experimental glomerulonephritis by the -1 Kidney mt 44:294—306, 1993 receptor antagonist: Inhibition of intercellular adhesion molecule-i 56. SAIo Y, OKIGAKI T, TAKAMIYA H, SENO S: Experimental autoim- expression. JAm Soc Nephrol 4:1695—1700, 1994 mune glomerulonephritis with pulmonary hemorrhage in rats. The 75. NISHIKAWA K, GUO YJ, MIYASAKA M, TAMATANI T, COLLINS AB, SY dose-effect relationship of the nephritogenic antigen from bovine MS, MCCLUSKEY RT, ANDRES G: Antibodies to intercellular adhesion glomerular basement membrane. J Clin Lab Immunol 15:199—204, molecule 1/lymphocyte function-associated antigen 1 prevent crescent 1984 formation in rat autoimmune glomerulonephritis. J Exp Med 177:667— 57. K..iiuu R, GAITONE VH II, NOELKEN ME, HUDSON BG: The a3 677, 1993 chain of type IV collagen induces autoimmune Goodpasture syn- 76. LAN HY, NIKOLIC-PATERSON Di, ZHENG 5, VANNICE JL, ATKINS RC: drome. Proc Nail Acad Sci 91:6201—6205, 1994 Suppression of experimental crescentic glomerulonephritis by the 58. KALLURI R, DANOFF TM, NEILSON EG: Murine anti-a3 (IV) collagen interleukin-1 receptor antagonist. Kidney mt 43:479—485, 1993 disease: A model of human Goodpasture syndrome and anti-GBM 77. LAN HY, ZARAMA M: Suppression of experimental crescentic glomer- ncphritis. JAm Soc Nephrol 6:833, 1995 ulonephritis by deoxyspergualin. JAm Soc Nephrol 3:1765—1774, 1993 59. BOLTON WK, MAY WJ, STtJIWII.I, BC, LUO A, Fox PL: Study of EHS 78. ESNAULT VLM, TESTA A, JAYNE DRW, S0UI,ILL0U JP, GUENEL J: type IV collagen lacking Goodpasture's epitope in glomerulonephri- Influence of immunoadsorption on the removal of tis. Kidney In! 47:404—410, 1995 autoantibodies in crescentic glomerulonephritis. Nephron 65:180—184, 60. SADO Y, KAGAWA M, NAITO I, OKIGAKI T: Properties of bovine 1993 nephritogenic antigen that induces anti-GBM nephritis in rats and its 79. BOUTAUD AA, KALLURI R, KAHSAI TZ, NOELKEN ME, HUDSON BG: similarity to the Goodpasture antigen. Virchows .4rch [B] 60:345—351, Goodpasturc Syndrome: Selective removal of anti-a3(TV) collagen 1991 antibodies. A potential therapeutic alternative to plasmapheresis. Exp 61. BOLTON WK, LU0 AM, Fox P, MAY WJ, Fox i: Goodpasture's Nephrol, in press epitope in the development of experimental autoimmune glomerulo- 80. BOLTON WK: The nature of clinical trials in nephrology. Kidney in! nephritis in rats. Kidney liii, in press 42:1061—1069, 1992 62. COUSER WG, WALLACE A, MONACO AP, LEWIS EJ: Successful renal 81. LEWIS Ei, BUSCH GJ, SCHUR PH: Gamma G globulin subgroup transplantation in patients with circulating antibody to glomerular composition of the glomerular deposits in human renal diseases. J Clin basement membrane: Report of two cases. Clin Nephrol 1:381—388, Invest 49:1103—1113, 1970 1973 82. BAKIMER R, KRAUSE I, ABU-SHAKARA M, TEPLIZKI-AMITAL H, ISEN- 63. WILSON CB, DixoN FJ: Antiglomerular basement membrane antibody BERG DA, ALARCON-SEGOVIA D, VILLAREAI. GM, SHOENFELD Y: The induced glomerulonephritis. Kidney In! 3:74—89, 1973 frequency of a common anti-DNA idiotype (16/6) in different popu- 64. JOhNSON JP, MOORE J JR, AUSTIN HA Ill, BALOW JE, ANTONOVYCH lations of patients with systemic lupus erythematosus. J Rheumatol TT, WILSON CB: Therapy of anti-glomerular basement membrane 18:1035—1037, 1991 antibody disease: Analysis of prognostic significance of clinical, patho- 83. BUSKILA D, SIIOENFELD Y: Anti-DNA idiotypes: Their pathogenic logic and treatment factors. Medicine 64:219—227, 1985 role in . Concepts Immunopathol 8:85—113, 1991 65. HIND CRK, LOCKWOOD CM, PETERS DK, PARASKEVAKOU H, EVANS 84. SHOENFELD Y, MozuS E: Pathogenic anti-idiotype (16/6 Id) in sys- Di, RuES AJ: Prognosis after immunosuppression of patients with temic lupus erythematosus. Rheumatol mt 11:91—93, 1991 crescentic ncphritis requiring dialysis. Lancet 1:263—264, 1983 85. REES AJ, PETERS DK, AMOS N, WELSH KI, BATCHELOR R: The 66. BRIGGS WA, JOHNSON JP, TEICHMAN 5, YEAGER HC, WILSON CB: influence in HLA linked genes on the severity of anti-GBM antibody Antiglomerular basement membrane antibody-mediated glomerulo- mediated nephritis. Kidney mt 26:444—447, 1983 nephritis and Goodpasture's syndrome. Medicine 58:348—361, 1979 86. TURNER N, MASON PJ, BROWN R, Fox M, POVEY S, REES A, PUSEY 67. BOLTON WK: Treatment of erescentic glomerulonephritis. Nephroloffv CD: Molecular cloning of the human Goodpasture antigen demon- 1:257—268, 1995 strates it to be the A3 chain of Type IV collagen. J Clin Invest 68. SIMPSON IJ, DOAK PB, WILLIAMS LC, BLACKLOCK HA, HILL RS, 89:592—601, 1992 TEAGUE CA, HERDSON PB, WILSON CB: Plasma exchange in Good- 87. SHEN G, BUTKOWSKI R, CHENG T, WIESLANDER i, KATZ A, CASS J, pasture's syndrome. Am J Nephrol 2:301—311, 1982 FISH Ai: Comparison of non-collagenous type IV collagen subunits in 69. BEROREM H, JERVELL J, BRODWALL E, FLATMARK A, MELLBYE 0: human glomerular basement membrane, alveolar basement mem- Goodpasture's syndrome: A report of seven patients including long- brane, and placenta. Connect Tissue Res 24:289—301, 1990 term follow-up of three who received a kidney transplant. Am J Med 88. STEBLAY RW, RUDOFSKY UH: Experimental autoimmune antiglo- 68:54—58, 1980 merular basement membrane antibody-induced glomerulonephritis. I. 70. PUSEY CD, REES AJ, EVANS Di, PETERS DK, LOCKWOOD CM: Plasma The effects of injecting sheep with human homologous or autologous exchange in focal necrotizing glomerulonephritis without anti-GBM lung basement membranes and complete Freund's adjuvant. Clin antibodies. Kidney mt 40:757—763, 1991 Immunol Immunopathol 27:65—80, 1983 71. FALK RJ, HOGAN S, CAREY TS, iENNETrE JC: Clinical course of 89. HUDSON BG, KALLURI R, GUNWAR 5, WEBER M, BALLESTER F, anti-neutrophil cytoplasmic -associated glomerulone- HUDSON iK, NOELKEN ME, SARRAS M, RICHARDSON WR, SAUS J, phritis and systemic vasculitis. Ann Intern Med 114:430—431, 1991 ABRAHAMSON DR, GLICK AD, HARALSON MA, HELDERMAN JH, 72. WILKOWSKI MJ, BOLTON WK: Systemic vasculitis: The biological basis, STONE WJ, iACOBSON HR: The pathogenesis of Alport syndrome in The Kidneys, edited by LEROY EC, New York, Marcel Dekker, involves type IV collagen molecules containing a3 (IV) chain: Evi- 1992, p 381 dence from anti-GBM nephritis after renal transplantation. Kidney In! 73. JAYNE DR, DAVIES MJ, Fox Ci, BLACK CM, LOCKWOOD CM: 42:179—187, 1992 Treatment of systemic vasculitis with pooled intravenous immuno- 90. ATKINS R: Nephrology Forum: Interleukin-1 in crescentic glomerulo- globulin. Lancet 337:1137—1139, 1991 nephritis. Kidney mt 48:576—586, 1995